{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T18:35:55Z","timestamp":1720722955111},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"US National Institute of General Medical Sciences","doi-asserted-by":"crossref","award":["U54GM104942","U54GM104942"],"award-info":[{"award-number":["U54GM104942","U54GM104942"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>The 2010 release of an abuse deterrent formulation (ADF) of OxyContin, a brand name prescription opioid, has been cited as a major driver for the reduction in prescription drug misuse and the associated increasing illicit opioid use and overdose rates. However, studies of this topic often do not account for changes in supplies of other prescription opioids that were widely prescribed before and after the ADF OxyContin release, including generic oxycodone formulations and hydrocodone. We therefore sought to compare the impact of the ADF OxyContin release to that of decreasing prescription opioid supplies in West Virginia (WV).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Opioid tablet shipment and overdose data were extracted from <jats:italic>The Washington Post<\/jats:italic> ARCOS (2006\u20132014) and the WV Forensic Drug Database (2005\u20132020), respectively. Locally estimated scatterplot smoothing (LOESS) was used to estimate the point when shipments of prescription opioids to WV began decreasing, measured via dosage units and morphine milligram equivalents (MMEs). Interrupted time series analysis (ITSA) was used to compare the impact LOESS-identified prescription supply changes and the ADF OxyContin release had on prescription (oxycodone and hydrocodone) and illicit (heroin, fentanyl, and fentanyl analogues) opioid overdose deaths in WV. Model fit was compared using Akaike Information Criteria (AIC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The majority of opioid tablets shipped to WV from 2006 to 2014 were generic oxycodone or hydrocodone,\u00a0not OxyContin. After accounting for a 6-month lag from ITSA models using the LOESS-identified change in prescription opioid shipments measured via dosage units (2011 Q3) resulted in the lowest AIC for both prescription (AIC = -188.6) and illicit opioid-involved overdoses (AIC = -189.4), indicating this intervention start date resulted in the preferred model. The second lowest AIC was for models using the ADF OxyContin release as an intervention start date.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>We found that illicit opioid overdoses in WV began increasing closer to when prescription opioid shipments to the state began decreasing, not when the ADF OxyContin release occurred. Similarly, the majority of opioid tablets shipped to the state for 2006\u20132014 were generic oxycodone or hydrocodone. This may indicate that diminishing prescription supplies had a larger impact on opioid overdose patterns than the ADF OxyContin release in WV.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13011-023-00587-2","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T13:03:02Z","timestamp":1704373382000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparing the effects of decreasing prescription opioid shipments and the release of an abuse deterrent OxyContin formulation on opioid overdose fatalities in WV: an interrupted time series study"],"prefix":"10.1186","volume":"19","author":[{"given":"Eric W.","family":"Lundstrom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline P.","family":"Groth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin L.","family":"Winstanley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Abate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon S.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"587_CR1","unstructured":"Centers for Disease Control and Prevention. Wide-ranging Online Data for Epidemiologic Research (WONDER). 2022 [cited 2022 Oct 19]. Available from: https:\/\/wonder.cdc.gov"},{"key":"587_CR2","doi-asserted-by":"crossref","unstructured":"Ciccarone D. The triple wave epidemic: supply and demand drivers of the US opioid Overdose crisis. Vol.\u00a071, International Journal of Drug Policy. Elsevier B.V.; 2019. p.\u00a0183\u20138.","DOI":"10.1016\/j.drugpo.2019.01.010"},{"key":"587_CR3","doi-asserted-by":"publisher","first-page":"106541","DOI":"10.1016\/j.ypmed.2021.106541","volume":"152","author":"RA Jenkins","year":"2021","unstructured":"Jenkins RA. The fourth wave of the US opioid epidemic and its implications for the rural US: a federal perspective. Prev Med (Baltim). 2021;152:106541.","journal-title":"Prev Med (Baltim)"},{"issue":"2","key":"587_CR4","first-page":"221","volume":"99","author":"A Van Zee","year":"2009","unstructured":"Van Zee A. The Promotion and Marketing of OxyContin : commercial triumph, Public Health Tragedy. Health Policy and Ethics. 2009;99(2):221\u20137.","journal-title":"Health Policy and Ethics"},{"key":"587_CR5","doi-asserted-by":"crossref","unstructured":"Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid Overdose crisis. Vol.\u00a034, Current Opinion in Psychiatry. Lippincott Williams and Wilkins; 2021. p.\u00a0344\u201350.","DOI":"10.1097\/YCO.0000000000000717"},{"issue":"3","key":"587_CR6","doi-asserted-by":"publisher","first-page":"e190665","DOI":"10.1001\/jamanetworkopen.2019.0665","volume":"2","author":"LZ Schieber","year":"2019","unstructured":"Schieber LZ, Guy GP, Seth P, Young R, Mattson CL, Mikosz CA, et al. Trends and patterns of Geographic Variation in Opioid Prescribing practices by State, United States, 2006\u20132017. JAMA Netw Open. 2019;2(3):e190665.","journal-title":"JAMA Netw Open"},{"key":"587_CR7","doi-asserted-by":"crossref","unstructured":"Sessler NE, Downing JM, Kale H, Chilcoat HD, Baumgartner TF, Coplan PM. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. Pharmacoepidemiol Drug Saf. 2014;23(12):1238\u201346. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24916486","DOI":"10.1002\/pds.3658"},{"key":"587_CR8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.drugpo.2017.05.050","volume":"46","author":"L Beletsky","year":"2017","unstructured":"Beletsky L, Davis CS. Today\u2019s fentanyl crisis: prohibition\u2019s Iron Law, revisited. International Journal of Drug Policy. 2017;46:156\u20139.","journal-title":"International Journal of Drug Policy"},{"key":"587_CR9","doi-asserted-by":"crossref","unstructured":"Beachler DC, Hall K, Garg R, Banerjee G, Li L, Boulanger L, et al. An evaluation of the Effect of the OxyContin\u00aeReformulation on Unintentional Fatal and non-fatal Overdose. Clinical Journal of Pain. 2022;","DOI":"10.1097\/AJP.0000000000001034"},{"issue":"3","key":"587_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/pme.12295","volume":"15","author":"TA Cassidy","year":"2014","unstructured":"Cassidy TA, DasMahapatra P, Black RA, Wieman MS, Butler SF. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. Pain Medicine. 2014;15(3):440\u201351.","journal-title":"Pain Medicine"},{"issue":"5","key":"587_CR11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1001\/jamapsychiatry.2014.3043","volume":"72","author":"TJ Cicero","year":"2015","unstructured":"Cicero TJ, Ellis MS. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States. JAMA Psychiatry. 2015;72(5):424.","journal-title":"JAMA Psychiatry"},{"key":"587_CR12","doi-asserted-by":"crossref","unstructured":"Evans WN, Lieber EMJ, Power P. How the Reformulation of OxyContin Ignited the Heroin Epidemic. Rev Econ Stat. 2019;101(1):1\u201315. Available from: https:\/\/direct.mit.edu\/rest\/article\/101\/1\/1\/58660\/How-the-Reformulation-of-OxyContin-Ignited-the","DOI":"10.1162\/rest_a_00755"},{"key":"587_CR13","unstructured":"Zhang S, Guth D. The OxyContin Reformulation Revisited: New Evidence From Improved Definitions of Markets and Substitutes. 2021 [cited 2023 Jan 8];1\u201349. Available from: http:\/\/arxiv.org\/abs\/2101.01128"},{"key":"587_CR14","doi-asserted-by":"publisher","unstructured":"Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse\u2010deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013;22(12):1274\u201382. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/pds.3522","DOI":"10.1002\/pds.3522"},{"key":"587_CR15","doi-asserted-by":"crossref","unstructured":"Cicero TJ, Inciardi JA, Mu\u00f1oz A. Trends in Abuse of OxyContin\u00ae and Other Opioid Analgesics in the United States: 2002\u20132004. J Pain. 2005;6(10):662\u201372. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526590005006565","DOI":"10.1016\/j.jpain.2005.05.004"},{"issue":"8","key":"587_CR16","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/pds.1452","volume":"16","author":"TJ Cicero","year":"2007","unstructured":"Cicero TJ, Surratt H, Inciardi JA, Munoz A. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol Drug Saf. 2007;16(8):827\u201340.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"587_CR17","unstructured":"Kenan K, Mack K, Paulozzi L. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000\u20132010. Open Med. 2012;6(2):e41-7. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23696768"},{"key":"587_CR18","doi-asserted-by":"publisher","unstructured":"Lopez Bernal J, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2016;46(1):dyw098. Available from: https:\/\/academic.oup.com\/ije\/article-lookup\/doi\/https:\/\/doi.org\/10.1093\/ije\/dyw098","DOI":"10.1093\/ije\/dyw098"},{"key":"587_CR19","unstructured":"The Washington Post. The Washington Post. 2020 [cited 2022 Oct 19]. Drilling into the DEA\u2019s pain pill database. Available from: https:\/\/www.washingtonpost.com\/graphics\/2019\/investigations\/dea-pain-pill-database\/?utm_term=.927f44f26372&itid=lk_inline_manual_2"},{"key":"587_CR20","unstructured":"Rich S, Diez MS, Vongkiatkajorn K. The Washington Post. 2019 [cited 2023 Feb 21]. How to download and use the DEA pain pills database. Available from: https:\/\/www.washingtonpost.com\/national\/2019\/07\/18\/how-download-use-dea-pain-pills-database\/"},{"key":"587_CR21","doi-asserted-by":"crossref","unstructured":"Winstanley EL, Zhang Y, Mashni R, Schnee S, Penm J, Boone J, et al. Mandatory review of a prescription drug monitoring program and impact on opioid and benzodiazepine dispensing. Drug Alcohol Depend. 2018;188:169\u201374. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871618302369","DOI":"10.1016\/j.drugalcdep.2018.03.036"},{"key":"587_CR22","unstructured":"Centers for Disease Control and Prevention. Calculating Total Daily Dose of Opioids for Safer Dosage. [cited 2022 Oct 19]. Available from: https:\/\/www.cdc.gov\/drugoverdose\/pdf\/calculating_total_daily_dose-a.pdf"},{"issue":"1","key":"587_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13011-021-00349-y","volume":"16","author":"CL Sedney","year":"2021","unstructured":"Sedney CL, Khodaverdi M, Pollini R, Dekeseredy P, Wood N, Haggerty T. Assessing the impact of a restrictive opioid prescribing law in West Virginia. Subst Abuse Treat Prev Policy. 2021;16(1):1\u201312.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"2","key":"587_CR24","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/00952990.2021.1981919","volume":"48","author":"Z Dai","year":"2022","unstructured":"Dai Z, Abate MA, Groth CP, Rucker T, Kraner JC, Mock AR, et al. Fentanyl and other opioid involvement in methamphetamine-related deaths. Am J Drug Alcohol Abuse. 2022;48(2):226\u201334.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"587_CR25","doi-asserted-by":"publisher","unstructured":"Barry CL. Fentanyl and the Evolving Opioid Epidemic: What Strategies Should Policy Makers Consider? Psychiatric Services. 2018;69(1):100\u20133. Available from: https:\/\/doi.org\/10.1176\/appi.ps.201700235","DOI":"10.1176\/appi.ps.201700235"},{"key":"587_CR26","unstructured":"Felbab-Brown V. Fentanyl and geopolitics Controlling opioid supply from China. 2020 Jan. Available from: www.brookings.edu\/about-us\/annual-report\/."},{"key":"587_CR27","doi-asserted-by":"publisher","unstructured":"O\u2019Donnell J, Gladden RM, Kariisa M, Mattson CL. Using death scene and toxicology evidence to define involvement of heroin, pharmaceutical morphine, illicitly manufactured fentanyl and pharmaceutical fentanyl in opioid overdose deaths, 38 states and the District of Columbia, January 2018\u2013December 2019. Addiction. 2022;117(5):1483\u201390. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1111\/add.15768","DOI":"10.1111\/add.15768"},{"key":"587_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2018.12.004","volume":"196","author":"Z Dai","year":"2019","unstructured":"Dai Z, Abate MA, Smith GS, Kraner JC, Mock AR. Fentanyl and fentanyl-analog involvement in drug-related deaths. Drug Alcohol Depend. 2019;196:1\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"587_CR29","unstructured":"RStudio Team. RStudio: Integrated Development for R. Boston, MA: RStudio, Inc.; 2022 [cited 2022 Mar 29]. Available from: http:\/\/www.rstudio.com\/"},{"key":"587_CR30","doi-asserted-by":"publisher","unstructured":"Schaffer AL, Dobbins TA, Pearson SA. Interrupted time series analysis using autoregressive integrated moving average (ARIMA) models: a guide for evaluating large-scale health interventions. BMC Med Res Methodol. 2021;21(1):58. Available from: https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12874-021-01235-8","DOI":"10.1186\/s12874-021-01235-8"},{"key":"587_CR31","doi-asserted-by":"crossref","unstructured":"Jacoby WG. Electoral inquiry section Loess: a nonparametric, graphical tool for depicting relationships between variables. Electoral Studies. 2000;19. Available from: www.elsevier.com\/locate\/electstud","DOI":"10.1016\/S0261-3794(99)00028-1"},{"key":"587_CR32","doi-asserted-by":"crossref","unstructured":"Ryan SE, Porth LS. A tutorial on the piecewise regression approach applied to bedload transport data. 2007. Available from: https:\/\/www.fs.usda.gov\/treesearch\/pubs\/27004","DOI":"10.2737\/RMRS-GTR-189"},{"key":"587_CR33","doi-asserted-by":"crossref","unstructured":"Ahmedani BK, Peterson EL, Wells KE, Lanfear DE, Williams LK. Policies and events affecting prescription opioid use for non-cancer pain among an insured patient population. Pain Physician. 2014;17(3):205\u201316. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24850102","DOI":"10.36076\/ppj.2014\/17\/205"},{"issue":"12","key":"587_CR34","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1513\/AnnalsATS.201701-022OC","volume":"14","author":"JP Stevens","year":"2017","unstructured":"Stevens JP, Wall MJ, Novack L, Marshall J, Hsu DJ, Howell MD. The critical care crisis of opioid overdoses in the United States. Ann Am Thorac Soc. 2017;14(12):1803\u20139.","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"587_CR35","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1001\/jamainternmed.2015.0914","volume":"175","author":"MR Larochelle","year":"2015","unstructured":"Larochelle MR, Zhang F, Ross-Degnan D, Wharam JF. Rates of opioid dispensing and Overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of Propoxyphene. JAMA Intern Med. 2015;175(6):978.","journal-title":"JAMA Intern Med"},{"key":"587_CR36","unstructured":"Mallama C. FDA review of PMR 3051-1 & 3051-3: Treatment Center Data to Assess the Impact of OxyContin Reformulation on Non-Oral and Overall Abuse of OxyContin. 2020 [cited 2023 Feb 19]. Available from: https:\/\/web.archive.org\/web\/20210306201006\/https:\/\/www.fda.gov\/media\/141973\/download"},{"key":"587_CR37","unstructured":"Secora A. FDA Review of PMR 3051-2 & 3051-4: Poison Control Center Study and Opioid Overdose Study Using Administrative Claims Dat. 2020 [cited 2023 Feb 19]. Available from: https:\/\/web.archive.org\/web\/20210306201006\/https:\/\/www.fda.gov\/media\/141973\/download"},{"key":"587_CR38","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.drugalcdep.2016.09.018","volume":"168","author":"SG Severtson","year":"2016","unstructured":"Severtson SG, Ellis MS, Kurtz SP, Rosenblum A, Cicero TJ, Parrino MW, et al. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug Alcohol Depend. 2016;168:219\u201329.","journal-title":"Drug Alcohol Depend"},{"key":"587_CR39","unstructured":"Nyugen M. Interrupted Time Series. In: A Guide on Data Analysis. 2022 [cited 2023 Jan 3]. Available from: https:\/\/bookdown.org\/mike\/data_analysis\/interrupted-time-series.html"},{"key":"587_CR40","doi-asserted-by":"crossref","unstructured":"Penfold RB, Zhang F. Use of interrupted time series analysis in evaluating health care quality improvements. Acad Pediatr. 2013;13(6 SUPPL.).","DOI":"10.1016\/j.acap.2013.08.002"},{"key":"587_CR41","doi-asserted-by":"crossref","unstructured":"Lopez Bernal J, Soumerai S, Gasparrini A. A methodological framework for model selection in interrupted time series studies. J Clin Epidemiol. 2018;103:82\u201391. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435617314117","DOI":"10.1016\/j.jclinepi.2018.05.026"},{"key":"587_CR42","doi-asserted-by":"crossref","unstructured":"Gilmour S, Degenhardt L, Hall W, Day C. Using intervention time series analyses to assess the effects of imperfectly identifiable natural events: a general method and example. BMC Med Res Methodol. 2006;6.","DOI":"10.1186\/1471-2288-6-16"},{"key":"587_CR43","doi-asserted-by":"publisher","unstructured":"LJUNG GM, BOX GEP. On a measure of lack of fit in time series models. Biometrika. 1978;65(2):297\u2013303. Available from: https:\/\/academic.oup.com\/biomet\/article-lookup\/doi\/https:\/\/doi.org\/10.1093\/biomet\/65.2.297","DOI":"10.1093\/biomet\/65.2.297"},{"key":"587_CR44","volume-title":"Model selection and Multimodel Inference: a practical information-theoretic Approach","author":"KP Burnhamn","year":"2002","unstructured":"Burnhamn KP, Anderson DR. Model selection and Multimodel Inference: a practical information-theoretic Approach. 2nd ed. New York, NY: Springer-Verlag New York, Inc.; 2002.","edition":"2"},{"key":"587_CR45","unstructured":"DEA Diversion Control Division. Fentanyl. 2016 [cited 2022 Sep 26]. Available from: https:\/\/www.dea.gov\/sites\/default\/files\/drug_chem_info\/fentanyl.pdf"},{"issue":"2","key":"587_CR46","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1056\/NEJMc1204141","volume":"367","author":"TJ Cicero","year":"2012","unstructured":"Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. New England Journal of Medicine. 2012;367(2):187\u20139.","journal-title":"New England Journal of Medicine"},{"key":"587_CR47","volume-title":"The opioid mortality epidemic in North America: do we understand the supply side dynamics of this unprecedented crisis?","author":"B Fischer","year":"2020","unstructured":"Fischer B, Pang M, Jones W. The opioid mortality epidemic in North America: do we understand the supply side dynamics of this unprecedented crisis? Vol.\u00a015, Substance Abuse: Treatment, Prevention, and Policy. BioMed Central Ltd.; 2020."},{"key":"587_CR48","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.drugpo.2017.01.010","volume":"41","author":"VA Greenfield","year":"2017","unstructured":"Greenfield VA, Paoli L. Research as due diligence: what can supply-side interventions accomplish and at what cost? International Journal of Drug Policy. 2017;41:162\u20133.","journal-title":"International Journal of Drug Policy"},{"issue":"2","key":"587_CR49","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1177\/1073110518782942","volume":"46","author":"N Werle","year":"2018","unstructured":"Werle N, Zedillo E. We can\u2019t go cold Turkey: why suppressing drug markets endangers society. Journal of Law, Medicine and Ethics. 2018;46(2):325\u201342.","journal-title":"Journal of Law, Medicine and Ethics"},{"key":"587_CR50","unstructured":"Centers for Disease Control and Prevention NC for IP and C. U.S. Opioid Dispensing Rate Maps. 2021."},{"issue":"1","key":"587_CR51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/pds.4078","volume":"26","author":"TJ Cicero","year":"2017","unstructured":"Cicero TJ, Ellis MS, Kasper ZA. Relative preferences in the abuse of immediate-release versus extended-release opioids in a sample of treatment-seeking opioid abusers. Pharmacoepidemiol Drug Saf. 2017;26(1):56\u201362.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"587_CR52","doi-asserted-by":"crossref","unstructured":"Wolff C, Dowd WN, Ali MM, McClellan C, Meinhofer A, Glos L, et al. The impact of the abuse-deterrent reformulation of extended-release OxyContin on prescription pain reliever misuse and heroin initiation. Addictive Behaviors. 2020;105.","DOI":"10.1016\/j.addbeh.2019.106268"},{"issue":"2","key":"587_CR53","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.drugpo.2013.10.004","volume":"25","author":"SG Mars","year":"2014","unstructured":"Mars SG, Bourgois P, Karandinos G, Montero F, Ciccarone D. \u2018Every \u201cnever\u201d i ever said came true\u2019: transitions from opioid pills to heroin injecting. International Journal of Drug Policy. 2014;25(2):257\u201366.","journal-title":"International Journal of Drug Policy"},{"key":"587_CR54","unstructured":"Finklea K. Illicit Drug Flows and Seizures in the United States: What Do We [Not] Know? [Internet]. 2019. Available from: www.crs.gov."},{"issue":"3","key":"587_CR55","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/ajad.13365","volume":"32","author":"J Sibbesen","year":"2023","unstructured":"Sibbesen J, Abate MA, Dai Z, Smith GS, Lundstrom E, Kraner JC, et al. Characteristics of xylazine-related deaths in West Virginia\u2014Xylazine\u2010related deaths. Am J Addict. 2023;32(3):309\u201313.","journal-title":"Am J Addict"},{"issue":"5","key":"587_CR56","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/eurpub\/ckt083","volume":"23","author":"JA Lopez Bernal","year":"2013","unstructured":"Lopez Bernal JA, Gasparrini A, Artundo CM, McKee M. The effect of the late 2000s financial crisis on suicides in Spain: an interrupted time-series analysis. Eur J Public Health. 2013;23(5):732\u20136.","journal-title":"Eur J Public Health"},{"issue":"12","key":"587_CR57","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.2105\/AJPH.2018.304781","volume":"108","author":"M Warner","year":"2018","unstructured":"Warner M, Hedegaard H. Identifying opioid Overdose deaths using vital Statistics Data. Am J Public Health. 2018;108(12):1587\u20139.","journal-title":"Am J Public Health"}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-023-00587-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13011-023-00587-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-023-00587-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T13:08:43Z","timestamp":1704373723000},"score":1,"resource":{"primary":{"URL":"https:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-023-00587-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["587"],"URL":"https:\/\/doi.org\/10.1186\/s13011-023-00587-2","relation":{},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"21 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was submitted to the Institutional Review Boards of West Virginia University, who determined it did not meet the definition of human subject research (IRB protocol number: 2211674154).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"None declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}